Skip to content

Lower Extremity Lymphedema Incidence and Quality of Life Following Surgery or Concurrent Chemoradiation for Gynecologic Cancer : A Prospective Trial

Lower Extremity Lymphedema Incidence and Quality of Life Following Surgery or Concurrent Chemoradiation for Gynecologic Cancer : A Prospective Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
TCTR
Registry ID
TCTR20240409005
Enrollment
226
Registered
2024-04-09
Start date
2023-11-24
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Leg edema Gynecologic cancer Underwent surgical staging with pelvic lymph node dissection Lower extremity lymphedema Cervical cancer, Endometrial cancer, Quality of life in gynecologic cancer

Interventions

Patients dianogsed of endometrial cancer and underwent surgical staging with pelvic lymphadenectomy ,Patients diagnosed of cervical cancer and underwent surgical staging with pelvic lymphadenectomy or
Diagnostic,Diagnostic
Endometrial cancer,Cervical cancer

Sponsors

none
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. Patients age 18 to 90 years, not pregnant or breastfeed 2. Diagnosed of Endometrial cancer or cervical cancer (histological proved) and had underwent CT or MRI for diagnosis 3. Not received any main treatment except the conization 4. Received main treatment as surgical staging with pelvic lymphadenectomy or concurrent chemoradiation 5. Be able to answer the questionnaire and to assess leg volume measurement 6. agree to participate

Exclusion criteria

Exclusion criteria: 1. Diagnosed of DVT or leg cellulitis 2. Alteration of conciousness or unable to answer the questionnaire 3. unable to communicate in Thai 4. Stage IV cancer with main treatment of chemotherapy

Design outcomes

Primary

MeasureTime frame
incidence ot lower extremity lymphedema in each gynecologic cancer baseline and 4-6 weeks after primary treatment, and 3 months post treament (in some patients) measurement of leg volume

Secondary

MeasureTime frame
Quality of life assessment baseline, 4-6 weeks after primary treatment, 3 months after treatment (in some patients) Questionnaire EORTC QLQ-CX24 (cervical cancer) or EORTC QLQ-EN24 (endometrial cancer) ,validate lymphedema questionnaire baseline, 4-6 weeks post treatment, 3 months post treatment in some patient Questionnaire of 13-item lymphedema compare to leg volume ,factors associated with lymphedema - logistic regression analysis

Countries

Thailand

Contacts

Public ContactNantakorn Pariyavatkul

Gynecologic oncology unit, Siriraj Hospital

nantakorn.dan133@gmail.com0994214241

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026